Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular assessments, including laboratory tests and clinical evaluations. While approaches may overlap with metastatic settings, adjuvant treatment often emphasizes early detection of immune-related AEs, as patients are generally healthier.
Video Player is loading.
Video content above is prompted by the following:
- What is your approach to AE monitoring and management with adjuvant nivolumab? Does your approach differ at all in adjuvant vs metastatic setting?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: Patient Counseling
Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
MIUC: Risk of Recurrence After Radical Cystectomy
Related Content
